Analyst Expect Big Moves From Allogene Therapeutics Inc (NASDAQ: ALLO)
Currently, there are 212.21M common shares owned by the public and among those 143.20M shares have been available to trade. The company’s stock has a 5-day price change of -11.72% and -19.29% over the past three months. ALLO shares are trading -46.95% year to date (YTD), with the 12-month market performance down to -60.49% lower. […]
Gains May Be On The Menu For Allogene Therapeutics Inc (NASDAQ: ALLO)
Currently, there are 212.21M common shares owned by the public and among those 143.20M shares have been available to trade. The company’s stock has a 5-day price change of -16.88% and -20.99% over the past three months. ALLO shares are trading -39.91% year to date (YTD), with the 12-month market performance down to -56.90% lower. […]
Allogene Therapeutics Inc (ALLO) Outlook Starting To Look Brighter?
Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $1.68, with 6.05 million shares of worth about $10.17 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.15% during that period and on April 30, 2025 the price saw a […]
Is There More Upside Ahead For Allogene Therapeutics Inc (NASDAQ: ALLO)
Allogene Therapeutics Inc (ALLO) concluded trading on Wednesday at a closing price of $4.15, with 4.08 million shares of worth about $16.92 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -6.95% during that period and on Wednesday February 7 the price saw a […]
Analyst Expect Big Moves From Allogene Therapeutics Inc (NASDAQ: ALLO)
Fidelity Management & Research Co recently announced the acquisition of new stake in Allogene Therapeutics Inc (NASDAQ:ALLO). The institutional investor has increased its shareholding in the Healthcare company by 0.91% to 25.14 million shares with purchase of 0.23 million shares. This fresh investment now brings its stake to 14.94% valued currently at $59.09 million. In […]
Allogene Therapeutics Inc (NASDAQ: ALLO): Hunting Genuine Value In Market Debris
Fidelity Management & Research Co recently announced the acquisition of new stake in Allogene Therapeutics Inc (NASDAQ:ALLO). The institutional investor has increased its shareholding in the Healthcare company by 0.91% to 25.14 million shares with purchase of 0.23 million shares. This fresh investment now brings its stake to 14.94% valued currently at $59.09 million. In […]